NOVARTIS AG-SPONSORED ADR
NVSNYSE🏆 #47 by market capEarnings Feb 2 · PostUS Equity
$156.07▼ $0.72 (−0.46%)
Market closed · at closeTrack NVS
Get earnings, price moves & breaking news on Telegram
24h▼ 0.5%
7d▼ 0.1%
14d▲ 3.8%
30d▲ 7.1%
ytd▲ 13.2%
1y▲ 28.2%
🏦Market Cap
$294.75B
Large Cap
📈Revenue Growth (YoY)
6.0%
Slowing
📊Gross Margin
74.3%
High
💵FCF Margin
27.9%
Strong
⚖️P/S Ratio
5.4x
Fair
Otter Score
80
Strong
Trading Snapshot
- Day Range
- $154.16 – $157.37
- 52-Week Range
- $121.57 – $170.46
- Volume (shares)
- 103,753
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.89B
- Next Earnings
- 2027-02-02
Fundamentals Snapshot
- Annual Revenue
- $54.81B
- Last Q Revenue
- $14.42B
- P/E Ratio
- 30.0
- P/S Ratio
- 5.4x
- EPS (TTM)
- $5.23
- Dividend Yield
- 2.86%
- Dilution (1yr)
- −3.7%
NOVARTIS AG-SPONSORED ADR
NVSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$54.8B▲ +6.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.0%▼ −0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$17.1B▲ +17.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$17.7B▲ +28.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.93B▼ −3.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$25.7B▼ −$5.9B YoY
StockOtter · stockotter.spaceAbout NOVARTIS AG-SPONSORED ADR
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100
Analyst Ratings
ⓘConsensus
Buy
34 analysts
Strong Buy6
Buy10
Hold16
Sell2
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.